Details for New Drug Application (NDA): 016466
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
NDA 016466 describes ARISTOSPAN, which is a drug marketed by Sandoz Inc and is included in one NDA. Additional details are available on the ARISTOSPAN profile page.
The generic ingredient in ARISTOSPAN is triamcinolone hexacetonide. There are fifty-one drug master file entries for this compound. Additional details are available on the triamcinolone hexacetonide profile page.
The generic ingredient in ARISTOSPAN is triamcinolone hexacetonide. There are fifty-one drug master file entries for this compound. Additional details are available on the triamcinolone hexacetonide profile page.
Summary for 016466
| Tradename: | ARISTOSPAN |
| Applicant: | Sandoz Inc |
| Ingredient: | triamcinolone hexacetonide |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 5MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 20MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
